NasdaqGS:DAWNBiotechs
Servier All Cash Deal Reframes Day One Biopharmaceuticals Valuation Story
Servier Pharmaceuticals has entered into a definitive agreement to acquire Day One Biopharmaceuticals, NasdaqGS:DAWN, in an all cash transaction.
The deal marks a material change in ownership, bringing Day One Biopharmaceuticals under Servier control and ending its status as an independent company once the transaction closes.
Day One Biopharmaceuticals focuses on developing and commercializing oncology therapies, a segment that has seen frequent partnerships, licensing arrangements, and...